Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
State Regulatory Surge, Federal Shifts Reshaping Workers’ Comp
Explore how rising regulatory activity, AI oversight and evolving workplace policies are reshaping workers’ comp claims management. In this Claims Journal article, Enlyte experts break down the compliance, litigation and operational risks organizations should be watching closely.
Turning Retrospective Review Into a Competitive Advantage
In this Enlyte Envision podcast episode, host Tom Kerr interviews experts Roland Kratzer and Alex Rose about optimizing utilization review programs for auto casualty payers.
Heat risk draws fresh scrutiny in workers compensation
Rising temperatures are putting new focus on heat-related workplace injuries and workers’ comp exposure. In this Business Insurance article, Michele Hibbert discusses emerging risks, evolving claims concerns and how employers and insurers are responding as heat scrutiny grows.
The Aging Workforce
Aging workforce strategies for workers’ comp help employers manage claim severity, injury prevention and return-to-work planning. Learn key risks.
Retail and Mail Order Prescriptions
Overall cost and utilization by claim were down in 2025 even with 6 of the top 10 therapeutic classes experiencing rising cost per script. Migraine medications rose by nearly 10%, representing the largest script cost gains driven in part by increases in brand Average Wholesale Price (AWP) including brand AWP for migraine medications increasing 2.4%. Utilization per claim also jumped in the migraine medication class (up 9.6%), while every other class within the top 10 (besides topicals, which rose 2.5%) experienced decreased utilization.
Plugged-In: EV Collision Insights Q1 2026
The U.S. share of repairable collision claims involving battery electric vehicles (BEVs) held steady at 3.33% in Q1 2026, unchanged from Q4 2025. Although sales of new BEVs grew modestly quarter over quarter, they remain 28% lower year over year. Several OEMs have scaled back production following increases in import tariffs and the expiration of federal tax incentives. Despite this near-term slowdown, BEVs are projected to reach approximately 29% of new vehicle sales and just over 10% of vehicles in operation by 2035, driving a steady increase in collision exposure.